ATM and B-cell chronic lymphocytic leukemia: In addition, we dissected the response to dual BCR and PARP inhibition based on the mutational status of known CLL driver genes, demonstrating that only patients harboring ATM mutations significantly correlated with a greater sensitivity to the drug combination (Fig. 4c).